Abstracts tagged "ANCA associated vasculitis"

Abstract Number: 0451 • ACR Convergence 2022
Incidence and Prevalence of ANCA-associated Vasculitis in Southern Sweden – a 23-year Study
Jens Rathmann¹, Mårten Segelmark², Martin Englund³ and Aladdin Mohammad⁴, ¹Rheumatology, Department of Clinical Sciences, Lund University, Lund, Skane Lan, Sweden, ²Nephrology, Department of Clinical Sciences, Lund University, Lund, Sweden, ³Lund University, Lund, Sweden, ⁴Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden
Background/Purpose: Epidemiologic studies in ANCA associated vasculitis (AAV) have demonstrated geographical variation between different countries as well as increasing incidence and prevalence during the last…
Abstract Number: 1072 • ACR Convergence 2022
Efficacy and Safety Assessment of a Rituximab Biosimilar in Patients with Granulomatosis with Polyangiitis (GPA)
Adil Vural¹, Komal Mushtaq¹, Chao Zhang¹, Mahmoud Alwakeel¹, Vickie Sayles¹, Kristine Duly², Carol Langford¹ and Rula Hajj-Ali³, ¹Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic, Fairview Park, OH, ³Cleveland Clinic, Hunting Valley, OH
Background/Purpose: A biosimilar is a medication that is highly similar to a biologic agent that is already approved by a regulatory organization. Considering the share…
Abstract Number: 1089 • ACR Convergence 2022
Prognostic Value of Proteinuria Monitoring in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Yeo jin lee¹, Soo Min Ahn², Ji Seon Oh³, Yong Gil Kim², Chang Keun Lee², Bin Yoo² and Seokchan Hong², ¹Asan medical center, Seoul, Republic of Korea, ²Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea, ³Department of Information Medicine, Big Data Research Center, Asan Medical Center, Seoul, Republic of Korea
Background/Purpose: Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is an autoimmune disease that can involve various organs systematically. Kidney involvement, one of the major manifestations of AAV,…
Abstract Number: 0435 • ACR Convergence 2022
Onset of ANCA-associated Vasculitides in Systemic Sclerosis: Phenotype, Management and Outcomes
deborah Eshagh¹, Thomas Quéméneur², Alexandre Karras³, Viviane Queyrel⁴, Jean Francois Augusto⁵, Christian Agard⁶, Vincent Audard⁷, Marion Couderc⁸, PIerre Duffau⁹, Cecile-Audrey Durel¹⁰, Stan Faguer¹¹, Noemie Jourde Chiche¹², Aurelie Lavergne¹³, Christian Lavigne⁵, Nicolas Limal¹, Amélie Servettaz¹⁴, Perrine Smets¹⁵, Alexis Regent¹⁶, Luc Mouthon¹⁶ and Benjamin Terrier¹⁶, ¹APHP, Paris, France, ²Valenciennes Hospital, Valenciennes, France, ³HEGP, Paris, France, ⁴CHU NIce, Nice, France, ⁵CHU Angers, Angers, France, ⁶Internal medicine, Nantes University Hospital, Nantes, France, ⁷CHU Henri Mondor, Creteil, France, ⁸University Hospital, Clermont-Ferrand, France, ⁹CHU Bordeaux, Bordeaux, France, ¹⁰CHU Lyon, Lyon, France, ¹¹CHU Toulouse, Toulouse, France, ¹²APHM, Marseille, France, ¹³CHU Rennes, Rennes, France, ¹⁴CHU Reims, Reims, France, ¹⁵CHU Clermont Ferrand, Clermont-Ferrand, France, ¹⁶National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France
Background/Purpose: Systemic sclerosis (SSc) is a complex autoimmune disease characterized by autoantibody production, skin and visceral fibrosis, and vasculopathy. The onset of ANCA-associated vasculitides (AAV)…
Abstract Number: 0452 • ACR Convergence 2022
Evaluation of the 2022 ACR/EULAR Classification Criteria for ANCA-Associated Vasculitis in a Population-based Cohort from Sweden
Jens Rathmann¹, Mårten Segelmark² and Aladdin Mohammad³, ¹Rheumatology, Department of Clinical Sciences, Lund University, Lund, Skane Lan, Sweden, ²Nephrology, Department of Clinical Sciences, Lund University, Lund, Sweden, ³Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden
Background/Purpose: The classification of ANCA- associated vasculitis (AAV) has been an area of controversy for many years. Available classifications and definitions are either overlapping and/or…
Abstract Number: 1073 • ACR Convergence 2022
Analysis of Clinical Outcomes in ANCA-associated Vasculitis Treated with Rituximab: Eighty Years a Single Center Experience in Japan
Soko Kawashima¹, Mitsumasa Kishimoto², Yoshinori Komagata³ and Shinya kaname⁴, ¹Kyorin University, Mitaka Tokyo, Japan, ²Kyorin University School of Medicine, Yokohama, Japan, ³Kyorin University School of Medicine, Tokyo, Japan, ⁴Kyorin University, Tokyo, Japan
Background/Purpose: Contrary to many Western countries, MPO-ANCA-associated vasculitis (MPO-AAV) is dominant in Japan. The therapeutic response to rituximab (RTX) may differ. Therefore, we conducted a…
Abstract Number: 1090 • ACR Convergence 2022
Pulmonary Function Testing (PFT) in Patients with Antineutrophil Cytoplasmic Antibodies (ANCA)-associated Vasculitis (AAV): Correlation with Radiologic Imaging
Johannes Dieterich¹, You-Shan Feng², Juliane Mahrhold¹, Abdallah El Rai³ and Bernhard Hellmich¹, ¹Department of Internal Medicine, Rheumatology and Immunology, Medius Kliniken, University of Tübingen, Kirchheim Teck, Germany, ²Institute for clinical Epidemiology and Biometry, University of Tübingen, Tübingen, Germany, ³Department of Radiology und Nuclear Medicine, Medius Kliniken, University of Tübingen, Nürtingen, Germany
Background/Purpose: Although pulmonary manifestations occur frequently in AAV, empirical evidence of their impact on pulmonary function is scarce. This project analyzed PFT data from a…
Abstract Number: 0437 • ACR Convergence 2022
Outcome Measures in Patients with Neurologic Involvement in ANCA-associated Vasculitis: Data from Multicenter Longitudinal Observational Study
Rula Hajj-Ali¹, Carol Langford², Chao Zhang², Leonard Calabrese², David Cuthbertson³, Nader Khalidi⁴, Curry Koening⁵, Carol McAlear⁶, Paul Monach⁷, Larry Moreland⁸, Christian Pagnoux⁹, Ulrich Specks¹⁰, Antoine Sreih¹¹, Kenneth J. Warrington¹⁰ and Peter Merkel¹², ¹Cleveland Clinic, Hunting Valley, OH, ²Cleveland Clinic, Cleveland, OH, ³University of South Florida, Tampa, FL, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Texas Dell Medical School, Austin, TX, ⁶Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ⁷VA Boston Healthcare System, Boston, MA, ⁸University of Colorado, Denver, CO, ⁹Mount Sinai Hospital, Toronto, ON, Canada, ¹⁰Mayo Clinic, Rochester, MN, ¹¹Bristol Myers Squibb, Philadelphia, PA, ¹²University of Pennsylvania, Philadelphia, PA
Background/Purpose: Neurologic involvement (NI) in ANCA-associated vasculitis (AAV) is common, occurring in approximately one-third of patients, and leads to significant and often chronic functional limitations…
Abstract Number: 0453 • ACR Convergence 2022
Validation of the 2022 – American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria in Patients with ANCA Associated Vasculitis
Aman Sharma¹, Prateek Deo¹, Shankar Naidu², Joydeep Samanta³, Sakshi Mittal³, Kusum Sharma³, Ritambhra Nada³, Varun Dhir⁴, sanjay jain² and Ranjana Minz², ¹PGIMER, Chandigarh, India, Chandigarh, India, ²Postgraduate Institute of Medical Education and Research, Chandigarh, India, ³PGIMER, Chandigarh, India, ⁴PGIMER, CHD, INDIA, Chandigarh, India
Background/Purpose: The purpose of this study was to validate the recently published 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for…
Abstract Number: 1074 • ACR Convergence 2022
Safety and Efficacy of Dupilumab in Patients with Relapsing and/or Refractory Eosinophilic Granulomatosis with Polyangiitis
Berengere Molina¹, Maria Letizia Urban², Roberto Padoan³, Pavel Novikov⁴, Camille Taillé⁵, Marco Caminati⁶, Christine Christides⁷, nicolas schleinitz⁸, Laura Moi⁹, Vincent Cottin¹⁰, bertrand godeau¹¹, Laurence Bouillet¹², Paolo Fraticelli¹³, Ann Knight¹⁴, Jan Walter Schroeder¹⁵, Sylvain Marchand-Adam¹⁶, Helder Gil¹⁷, Elena Gelain¹⁸, Giacomo Emmi² and Benjamin Terrier¹⁹, ¹Department of Internal Medicine, Cochin Hospital, Paris, France, ²Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ³University of Padova, Padova, Italy, ⁴Tareev’s Clinic, Sechenov First Moscow State Medical University, Moscow, Russia, ⁵Pulmonology department, Bichat Hospital, Paris, Ile-de-France, France, ⁶Verona University Hospital, University of Verona, Verona, Italy, ⁷Avignon hospital, Avignon, France, ⁸Aix Marseille university, AP-HM, Marseille, France, ⁹Centre hospitalier universitaire vaudois, Lausanne, Lausanne, Switzerland, ¹⁰Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, ¹¹Department of Internal Medicine, National Referral Center for Adult's Immune Cytopenias, Mondor Hospital, Créteil, France, ¹²Grenoble University Hospital, Grenoble, France, ¹³Department of Internal Medicine, Ospedali Riuniti di Ancona, Ancona, Italy, ¹⁴Akademiska sjukhuset, Uppsala, Sweden, ¹⁵ASST GOM Niguarda, Milano, Italy, ¹⁶Tours University Hospital, Tours, France, ¹⁷Besancon University Hospital, Besançon, France, ¹⁸Meyer Children’s University Hospital of Firenze, Florence, Italy, ¹⁹National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is an ANCA-associated vasculitides characterized by asthma, blood and tissue eosinophilia and systemic manifestations. Glucocorticosteroids (GCs)-dependent asthma and/or disabling…
Abstract Number: 1091 • ACR Convergence 2022
IgG Antibody Subclass Glycan Modifications in Patients with ANCA-Associated Vasculitis in Active vs Remission States – a Proof-of-Concept Study
Zachary Wallace¹, Tina Motazedi¹, Michelle Conroy¹, Claire Cook¹, John Stone², Hyon Choi³ and Robert Anthony¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ³MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: The Fc portion of IgG tends to be hypogalactosylated among patients with ANCA-associated vasculitis (AAV) compared with healthy controls1,2,3. Glycan modifications may affect antibody…
Abstract Number: 0438 • ACR Convergence 2022
Characterization of Interstitial Lung Disease in the Presence of Antineutrophil Cytoplasmic Antibodies
Khai-Tuan Andrew Bui¹, Rachel Richard², Ariane Drouin³, Nader Toban¹, Marianne Levesque⁴, Rosalie-Selene Meunier⁵, Carolyn Ross⁶ and Jean-Paul Makhzoum³, ¹Department of Medicine, Hopital du Sacre-Coeur de Montreal, University of Montreal, Montréal, QC, Canada, ²Department of Medicine, Hopital du Sacre-Coeur de Montreal, University of Montreal, Laval, QC, Canada, ³Vasculitis Clinic, Canadian Network for Research on Vasculitides (CanVasc), Department of Medicine, Hopital du Sacre-Coeur de Montreal, University of Montreal, Montréal, QC, Canada, ⁴Division of Respirology, Department of Medicine, Hopital du Sacre-Coeur de Montreal, University of Montreal, Montréal, QC, Canada, ⁵Hopital Sacre-Coeur, Universite de Montreal, Montréal, QC, Canada, ⁶University of Montreal, Montréal, QC, Canada
Background/Purpose: Various pulmonary manifestations may occur in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). ANCA-related interstitial lung disease (ILD) has recently been described in…
Abstract Number: 0454 • ACR Convergence 2022
Advantages and Disadvantages in Applying 2022 ACR/EULAR Classification Criteria to Conventionally Diagnosed Japanese GPA Patients
Ryo Kuwata¹, Yuko Shirota², Tsuyoshi Shirai³, Hiroyuki Yamashita¹, Hiroko Sato³, Tomoki Takeda², Yumiko Oka², Takao Kodera⁴, Hiroshi Kaneko¹, Junichi Kameoka⁵, Hiroshi Fujii³ and Tomonori Ishii⁶, ¹Division of Rheumatic diseases, National Center for Global Health and Medicine, Tokyo, Japan, ²Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, ³Department of Rheumatology, Tohoku University Hospital, Sendai, Japan, ⁴Department of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, ⁵Divison of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, ⁶Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Japan
Background/Purpose: The Chapel Hill Consensus Conference and the European Medicines Agency algorithm were commonly used to diagnose patients with granulomatosis with polyangiitis (GPA) 1）. Recently…
Abstract Number: 1075 • ACR Convergence 2022
Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis and a Vasculitic Phenotype
Benjamin Terrier¹, David Jayne², Bernhard Hellmich³, Jane Bentley⁴, Jonathan Steinfeld⁵, Steven Yancey⁶, Namhee Kwon⁷, Praveen Akuthota⁸, Paneez Khoury⁹, Lee Baylis¹⁰ and Michael Wechsler¹¹, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ²University of Cambridge, Cambridge, United Kingdom, ³Klinik für Innere Medizin, Rheumatologie & Immunologie, Medius Kliniken, Universität Tübingen, Plochingen, Germany, ⁴Clinical Statistics, GlaxoSmithKline, Brentford, United Kingdom, ⁵Clinical Sciences, Respiratory, GSK (affiliation at time of research), Philadelphia, PA, ⁶Respiratory Therapeutic Area, GSK (affiliation at the time of research), Research Triangle Park, NC, ⁷Clinical Sciences, Respiratory, GSK, Brentford, United Kingdom, ⁸Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of California, San Diego, CA, ⁹Human Eosinophil Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ¹⁰Global Medical Affairs, GlaxoSmithKline, Durham, NC, ¹¹Department of Medicine, National Jewish Health, Denver, CO
Background/Purpose: Patients with eosinophilic granulomatosis with polyangiitis (EGPA) can have vasculitic or eosinophilic phenotypes. The MIRRA study demonstrated that patients with EGPA spent more time…
Abstract Number: 1092 • ACR Convergence 2022
Intrarenal Synthesis of Complement C3 Localized to Distinct Vascular Compartments in ANCA-associated Renal Vasculitis
Désirée Tampe, Samy Hakroush and Björn Tampe, University Medical Center Göttingen, Göttingen, Germany
Background/Purpose: The activation of the complement system contributes essentially to its pathogenesis by autoantibody-antigen recognition directed against host cells in anti-neutrophil cytoplasmic antibody (ANCA)-associated renal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].